Eterna Therapeutics is pioneering the development of innovative off-the-shelf cellular therapies, specifically focusing on induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs). These iMSCs are engineered to express critical pro-inflammatory cytokines, such as IL-7 and IL-15, which are essential for enhancing T-cell anti-tumor activity. By utilizing a proprietary mRNA-based platform, Eterna is able to generate iPSCs in a scalable manner, ensuring a consistent and rejuvenated source for allogeneic therapies. This approach addresses the limitations associated with traditional mesenchymal stem cell therapies, such as batch-to-batch variability and inconsistent therapeutic outcomes due to factors like donor age and tissue origin.

Eterna's lead product candidate, ERNA-101, is currently in development and targets advanced solid tumors, including triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer. The therapy aims to selectively deliver IL-7 and IL-15 to tumor sites, minimizing systemic exposure and potential toxicity while maximizing therapeutic efficacy. By focusing on these advanced cellular therapies, Eterna Therapeutics is committed to improving treatment options for patients with difficult-to-treat diseases, thereby redefining the possibilities in cancer treatment.

United States

Eterna Therapeutics is developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. We and our strategic partners are advancing innovative nucleic acid and cell therapies that offer the hope of radically improving the health outcomes of patients with high unmet medical needs. We are committed to creating a world in which patients and their families have access to effective, life-changing treatments for serious illnesses.

Eterna Therapeutics

Company Details